DCM
FTH

Deuterium Capital Management’s Faeth Therapeutics FTH Stock Holding History

Deuterium Capital Management’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-550
Closed -$5.39K – 46
2024
Q4 		$5.39K Hold
550
– – 0.01% 35
2024
Q3 		$6.58K Hold
550
– – 0.01% 37
2024
Q2 		$6.82K Hold
550
– – 0.01% 55
2024
Q1 		$11.6K Hold
550
– – 0.02% 56
2023
Q4 		$7.61K Hold
550
– – 0.03% 49
2023
Q3 		$8.8K Hold
550
– – 0.02% 61
2023
Q2 		$12.5K Hold
550
– – 0.02% 97
2023
Q1 		$16.5K Sell
550
-45
-8% -$1.33K 0.03% 87
2022
Q4 		$17.7K Buy
+595
New +$17.5K 0.05% 63

Other funds holding FTH

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return

Deuterium Capital Management's FTH Position: Q1 2025 in Review

Deuterium Capital Management sold out of Faeth Therapeutics (FTH) in Q1 2025, closing a stake of 550 shares — an estimated $5.39K sold.

Deuterium Capital Management first reported a position in FTH in Q4 2022 and held it in 9 quarters. The position peaked at $17.7K in Q4 2022. 20 funds tracked by Wall St. Rank hold FTH as of Q1 2025.

  • Deuterium Capital Management reported no remaining Faeth Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Deuterium Capital Management sold 550 Faeth Therapeutics shares in Q1 2025, an estimated $5.39K.
  • Deuterium Capital Management first reported a position in Faeth Therapeutics in Q4 2022 and held it in 9 quarters.
  • Deuterium Capital Management's Faeth Therapeutics position peaked at $17.7K in Q4 2022.
  • 20 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q1 2025.

Based on Deuterium Capital Management's 13F filing for Q1 2025, filed 8 May 2025.